2-(3,5-Dimethyl-1,2-oxazol-4-yl)-5-methylbenzoic acid → (2-(3,5-Dimethylisoxazol-4-yl)-5-methylphenyl)((2S,3R)-3-methyl-2-(((5-(trifluoromethyl)pyridin-2-yl)amino)methyl)piperidin-1-yl)methanone

Beteiligte Stoffe

Rolle	Name	HCID	Einwaage
Edukt	2-(3,5-Dimethyl-1,2-oxazol-4-yl)-5-methylbenzoic acid	HCID 53225021	—
Edukt	N-(((2S,3R)-3-Methylpiperidin-2-yl)methyl)-5-(trifluoromethyl)pyridin-2-amine	HCID 89739447	—
Produkt	(2-(3,5-Dimethylisoxazol-4-yl)-5-methylphenyl)((2S,3R)-3-methyl-2-(((5-(trifluoromethyl)pyridin-2-yl)amino)methyl)piperidin-1-yl)methanone	HCID 117727827	—

Reaktionsschritte

The title compound was prepared following the same general protocol as described for Example A1, using 2-(3,5-dimethylisoxazol-4-yl)-5-methylbenzoic acid and N-(((2S,3R)-3-methylpiperidin-2-yl)methyl)-5-(trifluoromethyl)pyridin-2-amine. ESI-MS (m/z): 487 [M+1]+.

Herkunft & Nachweise

DOI	10.6084/m9.figshare.5104873.v1
Patentnummer	US09440982B2
Quelldatensatz	uspto-grants-2016_09
ORD ID	ord-2d7b1e587c4c418fb474701ae69c01d6
Quellennotiz	uspto-grants-2016_09